PDS Biotechnology (PDSB) said Thursday the US Food and Drug Administration cleared its new drug application for a clinical trial to evaluate a combination of its investigational immunotherapy Versamune MUC1 and PDS01ADC to treat metastatic colorectal cancer.
The company said the National Cancer Institute will lead the phase 1/2 trial under a Cooperative Research and Development Agreement.
The combination potentially targets tumors expressing MUC1, a protein linked to drug resistance and poor outcomes in several cancers, according to PDS.
Shares of the company were up 6.7% in recent premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.